Ipsen has presented long-awaited phase three results for elafibranor, a new class of medication for Primary Biliary Cholangitis. The disease, a genetic chronic liver condition, primarily affects women. Symptoms, which can take years to present, include fatigue and joint pain. Ipsen’s Jennifer Schranz noted that 51% of patients involved in the ELATIVE trial experienced significant benefits compared to 4% taking a placebo.
Fake Google Meet conference errors push infostealing malware
A new ClickFix campaign is using fraudulent Google Meet conference pages to lure users, showing bogus connectivity error messages that deliver info-stealing malware for Windows